Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AlphaVax has been cleared by the FDA to begin clinical trials evaluating vaccines developed with its alphavaccine technology to protect against both influenza and cytomegalovirus.
Subscribe to our email newsletter
The cytomegalovirus (CMV) alphavaccine, which contains three gene targets from CMV, will first be tested in healthy volunteers before being testing in target populations such as solid organ transplant recipients. Enrollment of subjects will begin in February 2007.
The company is also initiating the first of several trials evaluating alphavaccines for influenza. The first alphavaccine for influenza contains the hemagglutinin gene from a single strain of influenza. Enrollment of subjects will begin in April 2007. Subsequent trials will test additional vaccine candidates for seasonal as well as potentially pandemic strains of influenza.
“These trials will expand on our previous clinical experience with an HIV vaccine to two additional indications, influenza and CMV,” said Jeff Chulay, AlphaVax's chief medical officer.
“Advancing three vaccines for three different indications into the clinic validates the original design of our platform technology, which can be used against many different diseases.”